Several promising biotech companies crashed on Wall Street on Thursday morning after releasing preliminary data that suggested safety or efficacy concerns about experimental drugs they have in development.
The worst blows were dealt to the companies whose experimental drugs had poor safety profiles — namely, Canada’s Trillium Therapeutics and Achillion Pharmaceuticals of New Haven, Conn.
